Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Key aspects of progressive multiple sclerosis (PMS) distinguishing it from relapsing-remitting multiple sclerosis (RRMS)

From: The link of inflammation and neurodegeneration in progressive multiple sclerosis

- Time to disability progression is not driven by relapse rate, frequency or severity  
- Fewer active plaques (less inflammation and peripheral immune cell activation and fewer gadolinium enhancing lesions [signifying fewer blood-brain barrier breaches])  
- Compartmentalised inflammation within the central nervous system (CNS): meningeal inflammatory aggregates (lymphatic follicles-like)  
- More neurodegeneration: more demyelination and axonal loss in gray matter; more cortical pathology (subpial lesions are almost specific of PMS) and CNS atrophy  
- More diffuse abnormalities and tissue loss in the normal appearing CNS  
- Universal progressive spinal cord disease  
- Anti-inflammatory therapies less effective or ineffective